COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I FLVFLV REGNR2 LY-CoVLY RemdesivirRMD
HCQ study #24 of 260
5/2 Late treatment study
Mallat et al., Medicine (Baltimore), doi:10.1097/MD.0000000000023720 (preprint 5/2) (Peer Reviewed)
Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease: A retrospective study
Source   PDF   Share   Tweet
Very small retrospective analysis of 34 patients finding slower binary PCR viral clearance with HCQ. No information on severity for treatment versus control is provided. No deaths, ICU admission, or mechanical ventilation. Binary PCR does not distinguish replication-competence. HCQ treatment started very late for many patients with >= 9 days for 25%.

Mallat et al., 5/2/2020, retrospective, Abu Dhabi, Middle East, peer-reviewed, 8 authors.
time to viral-, 203.0% higher, relative time 3.03, p = 0.02, treatment 23, control 11.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 260 studies    Meta analysis
Please send us corrections, updates, or comments.